Solve Therapeutics Raises $120M to Advance Next-Generation ADC Platform
Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumors, has secured $120 million in an oversubscribed and…
Read More...
Read More...
